Filing Flows › Enanta Pharmaceuticals (ENTA) › Q4 FY24
Enanta Pharmaceuticals (ENTA) Q4 FY24 earnings results (fourth quarter fiscal 2024)
10-K filed Nov 27, 2024
Enanta Pharmaceuticals (ENTA) reported revenue of $14.6M for the fourth quarter fiscal 2024 (Q4 FY24), -23% from a year earlier and -19% from the quarter before. Operating margin was -204.4%, net loss $28.8M (197.3% of revenue).
Enanta Pharmaceuticals, Q4 FY24: revenue $14.6M (-23% year over year), operating margin -204.4%, net loss $28.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Q4 FY24 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.6M | -19% | -23% |
| Operating profit | −$29.9M | — | — |
| Net earnings | −$28.8M | — | — |
| Operating cash flow | −$10.4M | — | — |
What changed
Revenue was $14.6M in Q4 FY24, down 23% year over year and down 19% from the previous quarter.
Operating costs exceeded revenue by $29.9M, an operating margin of -204.4%. Total costs fell 11% while revenue fell 23%. The quarter ended with a net loss of $28.8M, wider than the previous quarter's $22.7M loss.
Operating cash flow was −$10.4M. Non-cash charges added back $479K of depreciation and amortization and $7.7M of share-based compensation. Working capital and other items added $10.2M. Capital expenditures of $9.0M exceeded it, leaving free cash flow of −$19.4M.
Questions
What was Enanta Pharmaceuticals' revenue in the fourth quarter fiscal 2024?
Enanta Pharmaceuticals (ENTA) reported revenue of $14.6M for the fourth quarter fiscal 2024 (Q4 FY24), -23% from a year earlier and -19% from the quarter before.
Was Enanta Pharmaceuticals profitable in the fourth quarter fiscal 2024?
Operating loss was $29.9M (-204.4% of revenue) and net loss $28.8M.